CD40LG and COVID-19: In summary, our study demonstrated that B-NHL patients who were recently treated with anti-CD20 antibodies or bendamustine had a diminished humoral response to COVID-19 vaccination and that serum IgM titer is a biomarker to predict the antibody response.